XOMA

XOMA Royalty Corporation

XOMA.US xoma.com
Price N/A
USD · NASDAQ
52-week range
22.29
45.22
Market Cap
710.16M
P/E Ratio
25.59
Forward P/E
19.49
Book Value
7.79
Div. Yield
N/A
% Institutions
85.33%
% Insiders
2.33%

1 Year

+57.7%

3 Year

+152.8%

10 Year

+204.3%
Description

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California. As of July 14, 2026, XOMA Royalty Corporation operates as a subsidiary of Ligand Pharmaceuticals Incorporated.

Company Information

Company Name
XOMA Royalty Corporation
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US98419J2069
CIK: 0000791908
CUSIP: G9825R107
Currency: USD
Full Time Employees: 14
Phone: 510 204 7200
Website: xoma.com
Fiscal Year End: December
IPO Date: Apr 05, 1989
Description:

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California. As of July 14, 2026, XOMA Royalty Corporation operates as a subsidiary of Ligand Pharmaceuticals Incorporated.

Address:

2200 Powell Street, EmeryVille, CA, United States, 94608

People

Directors & Officers

Name Title Year Born
Mr. Bradley Sitko Chief Investment Officer 1981
Mr. Jeffrey Trigilio Chief Financial Officer 1984
Juliane Snowden Head of Investor Relations NA
Ms. Maricel Perea Montano Chief Legal Officer & Corporate Secretary NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 04, 2025 Owen Hughes N/A Purchase 100.00K $25.05 $2.51M
Sep 22, 2025 Thomas M Burns N/A Sale 4.33K $35.99 $155.84K
May 20, 2025 Owen Hughes N/A Sale 25.64K $25.38 $650.67K
May 16, 2025 Bvf Partners L P/Il N/A Sale 392.72K $27.10 $10.64M

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Bvf Inc 2.59M Mar 31, 2026 14.65% $2.59 0.00%
Morgan Stanley - Brokerage Accounts 1.70M Mar 31, 2026 9.63% $0.00 -0.73%
FMR Inc 1.30M Mar 31, 2026 7.37% $0.00 12.14%
BlackRock Inc 646.91K Mar 31, 2026 3.66% $0.00 5.79%
Woodline Partners LP 640.00K Mar 31, 2026 3.62% $0.08 143.41%
Vanguard Capital Management, LLC 549.80K Mar 31, 2026 3.11% $0.00 0.00%
Opaleye Management Inc 338.37K Jun 30, 2026 1.91% $1.30 12.79%
Eckert Corp 239.32K Jun 30, 2026 1.35% $0.64 0.00%
GW&K Investment Management, LLC 232.14K Mar 31, 2026 1.31% $0.06 0.00%
Geode Capital Management, LLC 229.77K Mar 31, 2026 1.30% $0.00 3.70%
Millennium Management LLC 196.31K Jun 30, 2026 1.11% $0.00 -4.20%
State Street Corp 193.15K Mar 31, 2026 1.09% $0.00 10.43%
Dimensional Fund Advisors, Inc. 177.11K Jun 30, 2026 1.00% $0.00 32.80%
TLS Advisors LLC 114.87K Mar 31, 2026 0.65% $8.55 139.69%
Citadel Advisors Llc 98.64K Mar 31, 2026 0.56% $0.00 0.00%
Northern Trust Corp 93.49K Mar 31, 2026 0.53% $0.00 3.41%
Vanguard Portfolio Management, LLC 85.80K Mar 31, 2026 0.49% $0.00 0.00%
Bank of New York Mellon Corp 74.98K Mar 31, 2026 0.42% $0.00 9.65%
UBS Group AG 72.53K Mar 31, 2026 0.41% $0.00 178.47%
Stonepine Capital Management Llc 69.50K Mar 31, 2026 0.39% $0.87 -39.57%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Contrafund 944.12K 5.34% ▲ 10.48% Jun 30, 2026
2 Fidelity Contrafund Commingled Pl Cl S 363.91K 2.06% ▲ 12.39% Jun 30, 2026
3 Morgan Stanley Insight I 252.07K 1.43% ▲ 0.00% Jun 30, 2026
4 Morgan Stanley Insight 252.07K 1.43% ▲ 0.00% Jun 30, 2026
5 Arbitrage R 198.68K 1.12% ▲ 0.00% May 31, 2026
6 Fidelity Contrafund K6 195.98K 1.11% ▲ 10.50% Jun 30, 2026
7 Morgan Stanley Inst Inception I 172.89K 0.98% ▼ 1.07% Jun 30, 2026
8 Morgan Stanley Inception 172.89K 0.98% ▼ 1.07% Jun 30, 2026
9 MS INVF Global Insight Z 139.62K 0.79% ▲ 0.00% Mar 31, 2026
10 EQ/Morgan Stanley Small Cap Growth K 116.30K 0.66% ▲ 0.25% Jun 30, 2026

Financial Highlights

Market Cap: $710.16M
EBITDA: $8.30M
P/E Ratio: $25.59
PEG Ratio: $-0.42
Book Value: $7.79
Earnings/Share: $1.57
Profit Margin: 69.63%
Operating Margin: -3.90%
ROA (TTM): 1.28%
ROE (TTM): 34.23%
Revenue (TTM): $48.56M
Revenue/Share (TTM): $4.03
Earnings Growth (YOY): 207.90%
Revenue Growth (YOY): -22.60%

Valuation Metrics

Enterprise Value: $562.48M
Trailing P/E: 25.59
Forward P/E: 19.49

Shares Statistics

Shares Outstanding: 17.68M
Shares Float: 4.80M
% Insiders: 2.33%
% Institutions: 85.33%
Short % Float: 9.29%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$52.15M
Cost of Goods Sold
adjust
$-2.96M
Gross Profit
subtotal
$49.18M
SG&A
adjust
$-36.09M
R&D
adjust
$-1.71M
Operating Income
subtotal
$11.38M
Other / Non-Operating Items
adjust
$20.33M
Net Income
subtotal
$31.71M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about XOMA.US!